Truncated and modified amyloid-beta species.

[en] Alzheimer's disease pathology is closely connected to the processing of the amyloid precursor protein (APP) resulting in the formation of a variety of amyloid-beta (Aβ) peptides. They are found as insoluble aggregates in senile plaques, the histopathological hallmark of the disease. These peptides are also found in soluble, mostly monomeric and dimeric, forms in the interstitial and cerebrospinal fluid. Due to the combination of several enzymatic activities during APP processing, Aβ peptides exist in multiple isoforms possessing different N-termini and C-termini. These peptides include, to a certain extent, part of the juxtamembrane and transmembrane domain of APP. Besides differences in size, post-translational modifications of Aβ - including oxidation, phosphorylation, nitration, racemization, isomerization, pyroglutamylation, and glycosylation - generate a plethora of peptides with different physiological and pathological properties that may modulate disease progression.

Disciplines :

Neurology

Author, co-author :

Kummer, Markus P; Department of Neurology, University Hospital Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany

HENEKA, Michael ; Department of Neurology, University Hospital Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany , German Center for Neurodegenerative Diseases (DZNE), Holbeinstrasse 15, 53117 Bonn, Germany

External co-authors :

yes

Language :

English

Title :

Truncated and modified amyloid-beta species.

Publication date :

2014

Journal title :

Alzheimer's Research and Therapy

eISSN :

1758-9193

Publisher :

BioMed Central Ltd., England

Volume :

Issue :

Pages :

Peer reviewed :

Peer Reviewed verified by ORBi

Funding text :

The authors would like to thank Catherine Widmann, Dr Sascha Weggen and Dr Claus Pietrzik for discussion. This study was supported by the Deutsche Forschungsgemeinschaft (KFO177, TP4) to MTH and by grants of the INMiND project of the European Union to MTH. MTH is member of the DFG Cluster of Excellence ImmunoSensation.

Available on ORBilu :

since 07 May 2024

Statistics

Number of views

39 (0 by Unilu)

Number of downloads

13 (0 by Unilu)

More statistics

Scopus citations^®

257

Scopus citations^®
without self-citations

250

OpenCitations

221

OpenAlex citations

312

WoS citations^™

256

Bibliography

Alzheimer's disease. HW Querfurth, FM LaFerla, N Engl J Med 2010 362 329 344 10.1056/NEJMra0909142 20107219
Decreased clearance of CNS β-amyloid in Alzheimer's disease. KG Mawuenyega, W Sigurdson, V Ovod, L Munsell, T Kasten, JC Morris, KE Yarasheski, RJ Bateman, Science 2010 330 1774 1774 10.1126/science.1197623 21148344
Neuroinflammatory processes in Alzheimer's disease. MT Heneka, MK O'Banion, D Terwel, MP Kummer, J Neural Transm Vienna Austria 1996 2010 117 919 947
Amyloid precursor protein trafficking, processing, and function. G Thinakaran, EH Koo, J Biol Chem 2008 283 29615 29619 10.1074/jbc.R800019200 18650430
ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. P-H Kuhn, H Wang, B Dislich, A Colombo, U Zeitschel, JW Ellwart, E Kremmer, S Rossner, SF Lichtenthaler, EMBO J 2010 29 3020 3032 10.1038/emboj.2010.167 20676056
Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. R Vassar, BD Bennett, S Babu-Khan, S Kahn, EA Mendiaz, P Denis, DB Teplow, S Ross, P Amarante, R Loeloff, Y Luo, S Fisher, J Fuller, S Edenson, J Lile, MA Jarosinski, AL Biere, E Curran, T Burgess, JC Louis, F Collins, J Treanor, G Rogers, M Citron, Science 1999 286 735 741 10.1126/science.286.5440.735 10531052 (Pubitemid 29505878)
Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. P Seubert, C Vigo-Pelfrey, F Esch, M Lee, H Dovey, D Davis, S Sinha, M Schlossmacher, J Whaley, C Swindlehurst, Nature 1992 359 325 327 10.1038/359325a0 1406936
Reconstitution of gamma-secretase activity. D Edbauer, E Winkler, JT Regula, B Pesold, H Steiner, C Haass, Nat Cell Biol 2003 5 486 488 10.1038/ncb960 12679784 (Pubitemid 36592274)
γ-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. M Takami, Y Nagashima, Y Sano, S Ishihara, M Morishima-Kawashima, S Funamoto, Y Ihara, J Neurosci Off J Soc Neurosci 2009 29 13042 13052 10.1523/JNEUROSCI.2362-09.2009
Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. Y Qi-Takahara, M Morishima-Kawashima, Y Tanimura, G Dolios, N Hirotani, Y Horikoshi, F Kametani, M Maeda, TC Saido, R Wang, Y Ihara, J Neurosci Off J Soc Neurosci 2005 25 436 445 10.1523/JNEUROSCI.1575-04.2005 (Pubitemid 40105614)
Characterization of cerebrospinal fluid aminoterminally truncated and oxidized amyloid-β peptides. M Bibl, M Gallus, V Welge, S Lehmann, K Sparbier, H Esselmann, J Wiltfang, Proteomics Clin Appl 2012 6 163 169 10.1002/prca.201100082 22532452
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. C Haass, DJ Selkoe, Nat Rev Mol Cell Biol 2007 8 101 112 10.1038/nrm2101 17245412 (Pubitemid 46432529)
Generation of C-terminally truncated amyloid-β peptides is dependent on γ-secretase activity. D Beher, JDJ Wrigley, AP Owens, MS Shearman, J Neurochem 2002 82 563 575 10.1046/j.1471-4159.2002.00985.x 12153480 (Pubitemid 34835674)
A novel pathway for amyloid precursor protein processing. E Portelius, E Price, G Brinkmalm, M Stiteler, M Olsson, R Persson, A Westman-Brinkmalm, H Zetterberg, AJ Simon, K Blennow, Neurobiol Aging 2011 32 1090 1098 10.1016/j.neurobiolaging.2009.06.002 19604603
β-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. C Haass, AY Hung, MG Schlossmacher, DB Teplow, DJ Selkoe, J Biol Chem 1993 268 3021 3024 8428976 (Pubitemid 23070917)
Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs. E Portelius, B Van Broeck, U Andreasson, MK Gustavsson, M Mercken, H Zetterberg, H Borghys, K Blennow, J Alzheimers Dis 2010 21 1005 1012 20634579
A novel Aβ isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. E Portelius, RA Dean, MK Gustavsson, U Andreasson, H Zetterberg, E Siemers, K Blennow, Alzheimers Res Ther 2010 2 7 10.1186/alzrt30 20350302
Alpha-secretase mediated conversion of the amyloid precursor protein derived membrane stub C99 to C83 limits Aβ generation. S Jäger, S Leuchtenberger, A Martin, E Czirr, J Wesselowski, M Dieckmann, E Waldron, C Korth, EH Koo, M Heneka, S Weggen, CU Pietrzik, J Neurochem 2009 111 1369 1382 10.1111/j.1471-4159.2009.06420.x 19804379
Unusual phenotypic alteration of beta amyloid precursor protein (βAPP) maturation by a new Val-715 → Met βAPP-770 mutation responsible for probable early-onset Alzheimer's disease. K Ancolio, C Dumanchin, H Barelli, JM Warter, A Brice, D Campion, T Frébourg, F Checler, Proc Natl Acad Sci USA 1999 96 4119 4124 10.1073/pnas.96.7.4119 10097173 (Pubitemid 29169046)
Beta-amyloid peptide variants in brains and cerebrospinal fluid from amyloid precursor protein (APP) transgenic mice: comparison with human Alzheimer amyloid. H Schieb, H Kratzin, O Jahn, W Möbius, S Rabe, M Staufenbiel, J Wiltfang, HW Klafki, J Biol Chem 2011 286 33747 33758 10.1074/jbc.M111.246561 21795681
Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. N Sergeant, S Bombois, A Ghestem, H Drobecq, V Kostanjevecki, C Missiaen, A Wattez, J-P David, E Vanmechelen, C Sergheraert, A Delacourte, J Neurochem 2003 85 1581 1591 10.1046/j.1471-4159.2003.01818.x 12787077 (Pubitemid 36702570)
APP transgenic mice Tg2576 accumulate Aβ peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. W Kalback, MD Watson, TA Kokjohn, Y-M Kuo, N Weiss, DC Luehrs, J Lopez, D Brune, SS Sisodia, M Staufenbiel, M Emmerling, AE Roher, Biochemistry (Mosc) 2002 41 922 928 10.1021/bi015685+ (Pubitemid 34061994)
Amino-terminal deletions enhance aggregation of β-amyloid peptides in vitro. CJ Pike, MJ Overman, CW Cotman, J Biol Chem 1995 270 23895 23898 10.1074/jbc.270.41.23895 7592576
β-Amyloid degradation and Alzheimer's disease. DS Wang, DW Dickson, JS Malter, J Biomed Biotechnol 2006 2006 58406 17047308
Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells. J Wiltfang, H Esselmann, P Cupers, M Neumann, H Kretzschmar, M Beyermann, D Schleuder, H Jahn, E Rüther, J Kornhuber, W Annaert, B De Strooper, P Saftig, J Biol Chem 2001 276 42645 42657 10.1074/jbc.M102790200 11526104
Immunohistochemical localization of amyloid beta-protein with amino-terminal aspartate in the cerebral cortex of patients with Alzheimer's disease. T Arai, H Akiyama, K Ikeda, H Kondo, H Mori, Brain Res 1999 823 202 206 10.1016/S0006-8993(98)01366-3 10095028 (Pubitemid 29225510)
Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia. M Bibl, M Gallus, V Welge, H Esselmann, S Wolf, E Rüther, J Wiltfang, J Neural Transm Vienna Austria 1996 2012 119 805 813
The metalloprotease meprin β generates amino terminal-truncated amyloid β peptide species. J Bien, T Jefferson, M Causević T Jumpertz, L Munter, G Multhaup, S Weggen, C Becker-Pauly, CU Pietrzik, J Biol Chem 2012 287 33304 33313 10.1074/jbc.M112.395608 22879596
Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease. JL Wittnam, E Portelius, H Zetterberg, MK Gustavsson, S Schilling, B Koch, H-U Demuth, K Blennow, O Wirths, TA Bayer, J Biol Chem 2012 287 8154 8162 10.1074/jbc.M111.308601 22267726
Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Aβ42 accumulation in a novel Alzheimer transgenic model. C Casas, N Sergeant, J-M Itier, V Blanchard, O Wirths, N van der Kolk, V Vingtdeux, E van de Steeg, G Ret, T Canton, H Drobecq, A Clark, B Bonici, A Delacourte, J Benavides, C Schmitz, G Tremp, TA Bayer, P Benoit, L Pradier, Am J Pathol 2004 165 1289 1300 10.1016/S0002-9440(10)63388-3 15466394 (Pubitemid 39297734)
High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. A Güntert, H Döbeli, B Bohrmann, Neuroscience 2006 143 461 475 10.1016/j.neuroscience.2006.08.027 17008022 (Pubitemid 44716598)
Alanine-2 carbonyl is an oxygen ligand in Cu2+ coordination of Alzheimer's disease amyloid-beta peptide-relevance to N-terminally truncated forms. SC Drew, CL Masters, KJ Barnham, J Am Chem Soc 2009 131 8760 8761 10.1021/ja903669a 19496610
Amyloid plaque core protein in Alzheimer disease and Down syndrome. CL Masters, G Simms, NA Weinman, G Multhaup, BL McDonald, K Beyreuther, Proc Natl Acad Sci USA 1985 82 4245 4249 10.1073/pnas.82.12.4245 3159021 (Pubitemid 15053619)
Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia. H Lewis, D Beher, N Cookson, A Oakley, M Piggott, CM Morris, E Jaros, R Perry, P Ince, RA Kenny, CG Ballard, MS Shearman, RN Kalaria, Neuropathol Appl Neurobiol 2006 32 103 118 10.1111/j.1365-2990.2006.00696.x 16599940
N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits. Y Bouter, K Dietrich, JL Wittnam, N Rezaei-Ghaleh, T Pillot, S Papot-Couturier, T Lefebvre, F Sprenger, O Wirths, M Zweckstetter, TA Bayer, Acta Neuropathol (Berl) 2013 126 189 205 10.1007/s00401-013-1129-2
Amino-truncated amyloid beta-peptide (Aβ5-40/42) produced from caspase-cleaved amyloid precursor protein is deposited in Alzheimer's disease brain. K Takeda, W Araki, H Akiyama, T Tabira, FASEB J Off Publ Fed Am Soc Exp Biol 2004 18 1755 1757 (Pubitemid 39561674)
A novel monoclonal antibody specific for the amino-truncated beta-amyloid Aβ5-40/42 produced from caspase-cleaved amyloid precursor protein. KS Murayama, F Kametani, T Tabira, W Araki, J Neurosci Methods 2007 161 244 249 10.1016/j.jneumeth.2006.11.010 17207535 (Pubitemid 46466952)
Mass spectrometric characterization of amyloid-β species in the 7PA2 cell model of Alzheimer's disease. E Portelius, M Olsson, G Brinkmalm, U Rüetschi, N Mattsson, U Andreasson, J Gobom, A Brinkmalm, M Hölttä K Blennow, H Zetterberg, J Alzheimers Dis 2013 33 85 93 22886024
BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous system. N Mattsson, L Rajendran, H Zetterberg, M Gustavsson, U Andreasson, M Olsson, G Brinkmalm, J Lundkvist, LH Jacobson, L Perrot, U Neumann, H Borghys, M Mercken, D Dhuyvetter, F Jeppsson, K Blennow, E Portelius, PloS One 2012 7 31084 10.1371/journal.pone. 0031084 22328928
Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (Aβ); retards Aβ aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Hu, A Igarashi, M Kamata, H Nakagawa, J Biol Chem 2001 276 47863 47868 11604391
Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging. J Näslund, A Schierhorn, U Hellman, L Lannfelt, AD Roses, LO Tjernberg, J Silberring, SE Gandy, B Winblad, P Greengard, Proc Natl Acad Sci USA 1994 91 8378 8382 10.1073/pnas.91.18.8378 8078890 (Pubitemid 24273667)
Amyloid beta-peptide spin trapping. I: peptide enzyme toxicity is related to free radical spin trap reactivity. K Hensley, M Aksenova, JM Carney, M Harris, DA Butterfield, Neuroreport 1995 6 489 492 10.1097/00001756-199502000- 00021 7766850
Oxidation of methionine 35 attenuates formation of amyloid beta-peptide 1-40 oligomers. M Palmblad, A Westlind-Danielsson, J Bergquist, J Biol Chem 2002 277 19506 19510 10.1074/jbc.M112218200 11912198 (Pubitemid 34967462)
Methionine 35 oxidation reduces fibril assembly of the amyloid Aβ-(1-42) peptide of Alzheimer's disease. L Hou, I Kang, RE Marchant, MG Zagorski, J Biol Chem 2002 277 40173 40176 10.1074/jbc.C200338200 12198111 (Pubitemid 35215584)
Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. KJ Barnham, GD Ciccotosto, AK Tickler, FE Ali, DG Smith, NA Williamson, Y-H Lam, D Carrington, D Tew, G Kocak, I Volitakis, F Separovic, CJ Barrow, JD Wade, CL Masters, RA Cherny, CC Curtain, AI Bush, R Cappai, J Biol Chem 2003 278 42959 42965 10.1074/jbc.M305494200 12925530 (Pubitemid 37345908)
Phosphorylation of amyloid-beta at the serine 26 residue by human cdc2 kinase. NG Milton, Neuroreport 2001 12 3839 3844 10.1097/00001756-200112040- 00047 11726805 (Pubitemid 33105182)
Extracellular phosphorylation of the amyloid β-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease. S Kumar, N Rezaei-Ghaleh, D Terwel, DR Thal, M Richard, M Hoch, JM Mc Donald, U Wüllner, K Glebov, MT Heneka, DM Walsh, M Zweckstetter, J Walter, EMBO J 2011 30 2255 2265 10.1038/emboj.2011.138 21527912
Early intraneuronal accumulation and increased aggregation of phosphorylated Aβ in a mouse model of Alzheimer's disease. S Kumar, O Wirths, S Theil, J Gerth, TA Bayer, J Walter, Acta Neuropathol (Berl) 2013 125 699 709 10.1007/s00401-013-1107-8
Phosphorylation of amyloid-β peptide at serine 8 attenuates its clearance via insulin-degrading and angiotensin-converting enzymes. S Kumar, S Singh, D Hinze, M Josten, H-G Sahl, M Siepmann, J Walter, J Biol Chem 2012 287 8641 8651 10.1074/jbc.M111.279133 22267728
Peroxynitrite reactions and formation in mitochondria. R Radi, A Cassina, R Hodara, C Quijano, L Castro, Free Radic Biol Med 2002 33 1451 1464 10.1016/S0891-5849(02)01111-5 12446202 (Pubitemid 35351588)
Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. DA Butterfield, TT Reed, M Perluigi, C De Marco, R Coccia, JN Keller, WR Markesbery, R Sultana, Brain Res 2007 1148 243 248 17395167 (Pubitemid 46602178)
Proteomic identification of nitrated proteins in Alzheimer's disease brain. A Castegna, V Thongboonkerd, JB Klein, B Lynn, WR Markesbery, DA Butterfield, J Neurochem 2003 85 1394 1401 10.1046/j.1471-4159.2003.01786.x 12787059 (Pubitemid 36702552)
Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. MT Heneka, H Wiesinger, L Dumitrescu-Ozimek, P Riederer, DL Feinstein, T Klockgether, J Neuropathol Exp Neurol 2001 60 906 916 11556547 (Pubitemid 32880598)
Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. Y Vodovotz, MS Lucia, KC Flanders, L Chesler, QW Xie, TW Smith, J Weidner, R Mumford, R Webber, C Nathan, AB Roberts, CF Lippa, MB Sporn, J Exp Med 1996 184 1425 1433 10.1084/jem.184.4.1425 8879214 (Pubitemid 26354698)
Nitration of tyrosine 10 critically enhances amyloid β aggregation and plaque formation. MP Kummer, M Hermes, A Delekarte, T Hammerschmidt, S Kumar, D Terwel, J Walter, H-C Pape, S König, S Roeber, F Jessen, T Klockgether, M Korte, MT Heneka, Neuron 2011 71 833 844 10.1016/j.neuron.2011. 07.001 21903077
A central role for dityrosine crosslinking of amyloid-β in Alzheimer's disease. YK Al-Hilaly, TL Williams, M Stewart-Parker, L Ford, E Skaria, M Cole, WG Bucher, KL Morris, AA Sada, JR Thorpe, LC Serpell, Acta Neuropathol Commun 2013 1 83 10.1186/2051-5960-1-83 24351276
Heme binding induces dimerization and nitration of truncated β-amyloid peptide Aβ16 under oxidative stress. G Thiabaud, S Pizzocaro, R Garcia-Serres, J-M Latour, E Monzani, L Casella, Angew Chem Int Ed Engl 2013 52 8041 8044 10.1002/anie.201302989 23788407
Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid. A Halim, G Brinkmalm, U Rüetschi, A Westman-Brinkmalm, E Portelius, H Zetterberg, K Blennow, G Larson, J Nilsson, Proc Natl Acad Sci USA 2011 108 11848 11853 10.1073/pnas.1102664108 21712440
Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. H Mori, K Takio, M Ogawara, DJ Selkoe, J Biol Chem 1992 267 17082 17086 1512246
Dominant and differential deposition of distinct beta-amyloid peptide species, AβN3(pE), in senile plaques. TC Saido, T Iwatsubo, DM Mann, H Shimada, Y Ihara, S Kawashima, Neuron 1995 14 457 466 10.1016/0896-6273(95) 90301-1 7857653
Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide. J Sevalle, A Amoyel, P Robert, M-C Fournié-Zaluski, B Roques, F Checler, J Neurochem 2009 109 248 256 10.1111/j.1471-4159.2009.05950.x 19187443
Characterization of Aβ11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Aβ species in the pathogenesis of Alzheimer's disease. K Liu, I Solano, D Mann, C Lemere, M Mercken, JQ Trojanowski, VM-Y Lee, Acta Neuropathol (Berl) 2006 112 163 174 10.1007/s00401-006-0077-5
Beta-secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer's disease brain. JT Huse, K Liu, DS Pijak, D Carlin, VM-Y Lee, RW Doms, J Biol Chem 2002 277 16278 16284 10.1074/jbc.M111141200 11847218 (Pubitemid 34967916)
Glu11 site cleavage and N-terminally truncated Aβ production upon BACE overexpression. K Liu, RW Doms, VM-Y Lee, Biochemistry (Mosc) 2002 41 3128 3136 10.1021/bi015800g (Pubitemid 34184644)
Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. S Schilling, T Hoffmann, S Manhart, M Hoffmann, H-U Demuth, FEBS Lett 2004 563 191 196 10.1016/S0014-5793(04)00300-X 15063747 (Pubitemid 38471597)
Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease-like pathology. S Schilling, U Zeitschel, T Hoffmann, U Heiser, M Francke, A Kehlen, M Holzer, B Hutter-Paier, M Prokesch, M Windisch, W Jagla, D Schlenzig, C Lindner, T Rudolph, G Reuter, H Cynis, D Montag, H-U Demuth, S Rossner, Nat Med 2008 14 1106 1111 10.1038/nm.1872 18836460
Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta. H Cynis, E Scheel, TC Saido, S Schilling, H-U Demuth, Biochemistry (Mosc) 2008 47 7405 7413 10.1021/bi800250p (Pubitemid 351991019)
Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate Aβ formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice. S Jawhar, O Wirths, S Schilling, S Graubner, H-U Demuth, TA Bayer, J Biol Chem 2011 286 4454 4460 10.1074/jbc.M110.185819 21148560
Toxicity of pyroglutaminated amyloid beta-peptides 3(pE)-40 and -42 is similar to that of Aβ1-40 and -42. TL Tekirian, AY Yang, C Glabe, JW Geddes, J Neurochem 1999 73 1584 1589 10501204 (Pubitemid 29440160)
N-truncated amyloid-β oligomers induce learning impairment and neuronal apoptosis. I Youssef, S Florent-Béchard, C Malaplate-Armand, V Koziel, B Bihain, J-L Olivier, B Leininger-Muller, B Kriem, T Oster, T Pillot, Neurobiol Aging 2008 29 1319 1333 10.1016/j.neurobiolaging.2007.03.005 17459527 (Pubitemid 351981997)
The Aβ3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length Aβ W He, CJ Barrow, Biochemistry (Mosc) 1999 38 10871 10877 10.1021/bi990563r (Pubitemid 29404419)
Transient intraneuronal Aβ rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. DZ Christensen, SL Kraus, A Flohr, M-C Cotel, O Wirths, TA Bayer, Acta Neuropathol (Berl) 2008 116 647 655 10.1007/s00401-008-0451-6
Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease. T Kawarabayashi, LH Younkin, TC Saido, M Shoji, KH Ashe, SG Younkin, J Neurosci 2001 21 372 381 11160418 (Pubitemid 32107428)
Intraneuronal pyroglutamate-Aβ 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. O Wirths, H Breyhan, H Cynis, S Schilling, H-U Demuth, TA Bayer, Acta Neuropathol (Berl) 2009 118 487 496 10.1007/s00401-009-0557-5
Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Aβ is induced by pyroglutamate-Aβ formation. A Alexandru, W Jagla, S Graubner, A Becker, C Bäuscher, S Kohlmann, R Sedlmeier, KA Raber, H Cynis, R Rönicke, KG Reymann, E Petrasch-Parwez, M Hartlage-Rübsamen, A Waniek, S Rossner, S Schilling, AP Osmand, H-U Demuth, S von Hörsten, J Neurosci Off J Soc Neurosci 2011 31 12790 12801 10.1523/JNEUROSCI.1794-11.2011
Aspartate-bond isomerization affects the major conformations of synthetic peptides. GI Szendrei, H Fabian, HH Mantsch, S Lovas, O Nyéki, I Schön, L Otvos Jr, Eur J Biochem FEBS 1994 226 917 924 10.1111/j.1432-1033. 1994.t01-1-00917.x
Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. AE Roher, JD Lowenson, S Clarke, C Wolkow, R Wang, RJ Cotter, IM Reardon, HA Zürcher-Neely, RL Heinrikson, MJ Ball, J Biol Chem 1993 268 3072 3083 8428986 (Pubitemid 23070928)
Synthetic post-translationally modified human Aβ peptide exhibits a markedly increased tendency to form beta-pleated sheets in vitro. H Fabian, GI Szendrei, HH Mantsch, BD Greenberg, L Otvös Jr, Eur J Biochem FEBS 1994 221 959 964 10.1111/j.1432-1033.1994.tb18811.x (Pubitemid 24146195)
Isoaspartate formation at position 23 of amyloid beta peptide enhanced fibril formation and deposited onto senile plaques and vascular amyloids in Alzheimer's disease. T Shimizu, H Fukuda, S Murayama, N Izumiyama, T Shirasawa, J Neurosci Res 2002 70 451 461 10.1002/jnr.10350 12391606 (Pubitemid 35222382)
Synthesis, aggregation, and neurotoxicity of the Alzheimer's Aβ1-42 amyloid peptide and its isoaspartyl isomers. H Fukuda, T Shimizu, M Nakajima, H Mori, T Shirasawa, Bioorg Med Chem Lett 1999 9 953 956 10.1016/S0960-894X(99) 00121-3 10230618 (Pubitemid 29179887)
Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of Aβ peptides of Alzheimer's disease. YM Kuo, S Webster, MR Emmerling, N De Lima, AE Roher, Biochim Biophys Acta 1998 1406 291 298 10.1016/S0925-4439(98)00014-3 9630681 (Pubitemid 28269312)
The presence of isoaspartic acid in β-amyloid plaques indicates plaque age. MI Fonseca, E Head, P Velazquez, CW Cotman, AJ Tenner, Exp Neurol 1999 157 277 288 10.1006/exnr.1999.7058 10364440 (Pubitemid 29260736)
Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. T Iwatsubo, TC Saido, DM Mann, VM Lee, JQ Trojanowski, Am J Pathol 1996 149 1823 1830 8952519 (Pubitemid 26415203)
Beta-amyloid racemized at the Ser26 residue in the brains of patients with Alzheimer disease: implications in the pathogenesis of Alzheimer disease. T Kubo, Y Kumagae, CA Miller, I Kaneko, J Neuropathol Exp Neurol 2003 62 248 259 12638729 (Pubitemid 36330676)
Racemization of Asp23 residue affects the aggregation properties of Alzheimer amyloid beta protein analogues. T Tomiyama, S Asano, Y Furiya, T Shirasawa, N Endo, H Mori, J Biol Chem 1994 269 10205 10208 8144598
Racemization of the aspartic acid residue of amyloid-β peptide by a radical reaction. K Tambo, T Yamaguchi, K Kobayashi, E Terauchi, I Ichi, S Kojo, Biosci Biotechnol Biochem 2013 77 416 418 23391937
Simultaneous determination of post-translational racemization and isomerization of N-terminal amyloid-beta in Alzheimer's brain tissues by covalent chiral derivatized ultra-performance liquid chromatography tandem mass spectrometry. K Inoue, D Hosaka, N Mochiuki, H Akatsu, K Tsutsumiuchi, Y Hashizume, N Matsukawa, T Yamamoto, T Toyo'oka, Anal Chem 2013 86 797 804 24283798
Evaluation of the performance of novel Aβ isoforms as theragnostic markers in Alzheimer's disease: from the cell to the patient. E Portelius, MK Gustavsson, H Zetterberg, U Andreasson, K Blennow, Neurodegener Dis 2012 10 138 140 10.1159/000334537 22302034
Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. V Welge, O Fiege, P Lewczuk, B Mollenhauer, H Esselmann, H-W Klafki, S Wolf, C Trenkwalder, M Otto, J Kornhuber, J Wiltfang, M Bibl, J Neural Transm Vienna Austria 1996 2009 116 203 212
Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias. M Bibl, B Mollenhauer, P Lewczuk, H Esselmann, S Wolf, M Otto, J Kornhuber, E Rüther, J Wiltfang, Dement Geriatr Cogn Disord 2011 31 37 44 10.1159/000322370 21135556
Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. M Britschgi, CE Olin, HT Johns, Y Takeda-Uchimura, MC LeMieux, K Rufibach, J Rajadas, H Zhang, B Tomooka, WH Robinson, CM Clark, AM Fagan, DR Galasko, DM Holtzman, M Jutel, JA Kaye, CA Lemere, J Leszek, G Li, ER Peskind, JF Quinn, JA Yesavage, JA Ghiso, T Wyss-Coray, Proc Natl Acad Sci USA 2009 106 12145 12150 10.1073/pnas.0904866106 19581601
Reduced levels of IgM autoantibodies against N-truncated pyroglutamate Aβ in plasma of patients with Alzheimer's disease. A Marcello, O Wirths, T Schneider-Axmann, M Degerman-Gunnarsson, L Lannfelt, TA Bayer, Neurobiol Aging 2011 32 1379 1387 10.1016/j.neurobiolaging.2009.08.011 19781815
Pyroglutamate-Aβ 3 and 11 colocalize in amyloid plaques in Alzheimer's disease cerebral cortex with pyroglutamate-Aβ 11 forming the central core. CP Sullivan, EA Berg, R Elliott-Bryant, JB Fishman, AC McKee, PJ Morin, MA Shia, RE Fine, Neurosci Lett 2011 505 109 112 10.1016/j.neulet.2011. 09.071 22001577